DSE/SQURPHARMA (DSE/SQURPHARMA)
Dhaka Stock Exchange: DSE/SQURPHARMA · BDT
BDT 219
+0.00 (0.0%)· Recorded snapshot
| Market cap | 194B | |
|---|---|---|
| Revenue (ttm) | 83.5B | |
| Net income (ttm) | 25.9B | |
| EPS (ttm) | BDT 29.2 | |
| Shares out | 886.5M | |
| P/E (trailing) | 7.5x | |
| P/E (forward) | 6.8x | |
| Dividend | BDT 12.0 (5.48%) | |
| Volume | 238,797 | |
| Beta | 0.11 |
Market data
Price
Recent price action with selectable time range.
Financial snapshot
- Revenue (ttm)
- 83.5B
- Net income (ttm)
- 25.9B
- EPS (ttm)
- BDT 29.2
- P/E (trailing)
- 7.5x
- P/E (forward)
- 6.8x
- Market cap
- 194B
Fair-value bridge
- Current price
- BDT 219
In the news
Latest news · DSE/SQURPHARMA
Recent company headlines from major financial publishers.
Valuation
- Market cap
- 194B
- P/E (trailing)
- 7.5x
- P/E (forward)
- 6.8x
- P/S
- 2.3x
- P/B
- 1.3x
- EV / EBITDA
- 4.6x
Profitability
- Gross margin
- 48.2%
- Operating margin
- 26.1%
- ROE
- 18.1%
- ROA
- 9.1%
- ROIC
- 20.5%
Balance sheet
- Debt / equity
- 0.00
- Current ratio
- 13.78
- Quick ratio
- 11.26
Trading
- Beta
- 0.11
- Volume
- 238,797
- Dividend yield
- 5.5%
Calendar
Next earnings
Upcoming earnings date and setup when available.
Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector percentile context
Refreshed 2026-10-29 13:30 UTC
Forward P/E6.8
P25 n/aP50 n/aP75 n/a
Trailing P/E7.5
P25 n/aP50 n/aP75 n/a
ROE18.1
P25 n/aP50 n/aP75 n/a
ROIC20.5
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
S&P 500+0.5%
Nasdaq Composite-2.4%
Dow Jones Industrial Average+1.8%
Russell 2000+1.8%
All DSE/SQURPHARMA indicators
Market & fundamental data
Available fields
249
Groups with data
10
Currency
BDT
Showing 249 of 249 available metrics for this ticker.
Deeper analysis on DSE/SQURPHARMA
14 sections in the full report · jump straight to what you need
Forecast
Base and Bull forecast paths with report-date return framing.
Valuation
Fair-value bridge, DCF, owner earnings, and peer multiples.
Sensitivity
Cost-of-equity and terminal-growth stress table.
Risks
Kill scenarios, soft-pass flags, and downside catalysts.
Earnings
Next earnings setup and beat / inline / miss thresholds.
Position sizing
Entry, exit, conviction, and quarterly monitoring rules.
Financials
Revenue, margins, cash flow, and balance-sheet context.
Peers
Relative valuation and profitability against the cohort.
Moat
Economic-profit evidence and competitive advantage risk.
Industry cycle
Sector phase, capital cycle, and secular tailwinds.
Scorecard
Six-factor overlay and 9-category weighted scorecard.
Recommendation
Final action, action steps, opportunity, and biggest risk.
Perspectives
Growth, value, and income investor reads.
Archive
Prior published reports and rating changes.
Frequently asked questions
About this DSE/SQURPHARMA report
Is a complete DSE/SQURPHARMA research report available?
No complete published report is available for dse/SQURPHARMA (DSE/SQURPHARMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.